Background/Purpose: This study compared the effects of three induction doses of anti-vascular endothelial growth factor (anti-VEGF) on diabetic macular edema (DME) with that of long-term treatment using biomarkers to find out the predictability potential of early response to anti-VEGF treatment for the long-term restorative effect. Methods: We retrospectively reviewed the clinical and optical coherence tomography (OCT) data of 71 DME eyes treated with three monthly anti-VEGF doses and followed for 1 year. BCVA, central subfield thickness (CST), subretinal fluid (SRF), intraretinal cysts, hyperreflective foci (HF), disorganization of inner retinal layers (DRILs), ellipsoid zone/external limiting membrane (EZ/ELM) integrity, and vitreoretinal relationships were assessed at baseline, 3, 6, and 12 months. Results: Patients (50.7% male) had a mean follow-up of 12 months. After three anti-VEGF doses, 19 eyes required no additional injections, 25 continued anti-VEGF, 20 switched to dexamethasone implants, and seven received combination therapy. Best corrected visual acuity (BCVA) improved from 0.52 to 0.40 logMAR at 3 months, 0.30 at 6 months, and stabilized at 0.40 at 12 months. CST decreased from 406 µm to 317 µm at 3 months and 307 µm at 12 months. Significant early improvements in BCVA, CST, SRF, and intraretinal cysts were sustained in the long-term follow-up. HF reduction became significant after 6 months, while DRIL and EZ/ELM integrity remained unchanged. Conclusions: The improvement of OCT biomarkers in DME patients supported that intravitreal anti-VEGF significantly restored the retinal microstructure, which was already evident at 3 months in the control after anti-VEGF induction.
Tamoxifen is a widely used agent for the treatment of breast cancer worldwide. Despite its significant efficacy in breast cancer, serious side effects may occur with long-term or high-dose use. One of these side effects is tamoxifen retinopathy (TR). Tamoxifen retinopathy typically presents with bilateral visual impairment, crystalline deposits, and changes in the foveal reflex during fundus examination. Although characteristic features can be observed with multimodal imaging, it may be confused with various retinal pathologies. One of the primary conditions considered in the differential diagnosis of TR is macular telangiectasia type 2 (Mac-Tel 2). In this case presentation, we aim to share the differential diagnosis process of TR and highlight the distinguishing features from Mac-Tel 2 in a female patient who presented with decreased vision, based on the patient’s history, detailed fundoscopic examination findings, and multimodal imaging.
The aim of this study was to evaluate systemic and environmental risk factors, clinical findings and surgical trends in patients admitted to our clinic with the diagnosis of dermatochalasis. Between January and March 2024, 114 patients with upper eyelid dermatochalasis were retrospectively analyzed cross-sectionally. Demographic data, history of systemic disease, surgical history, presenting complaints, tear tests (Schirmer, tear breakup time (TBUT)) and dermatochalasis grades were recorded. In the patient cohort, females constituted 66.66%, with a mean age of 53.08±6.35 years. The predominant complaint was a sensation of heaviness or fatigue in the upper eyelid, as reported by 41.22% of the patients. A substantial 70.17% of the participants presented with at least one systemic illness, with diabetes mellitus, hypertension, thyroid disorders, and rheumatologic diseases being the most common. Symptoms of dry eye were observed in 31.57% of the patients, with an average Schirmer test result of 11.03±3.07 mm and a TBUT of 5.87±1.86 seconds. No significant correlation was found between Schirmer and TBUT values and the severity of dermatochalasis (p>0.05). Among the patients, 37.71% were considering surgery, with 65.11% seeking it for cosmetic reasons and 34.88% for functional purposes. Dermatochalasis is a complex condition associated with functional and systemic effects and aesthetic problems. A history of systemic disease, dry eye symptoms and visual field limitation should be considered in managing the disease. Therefore, a multidisciplinary approach should be adopted, and patient expectations should be considered in treatment planning. Prospective studies with a large sample size may better elucidate the etiopathogenesis and patient management.
Stem cells have been used for therapeutic purposes in many areas of medicine for many years. Depending on the tissues from which they are derived and their characteristics, stem cells can be classified into various groups. Some types of stem cells have the capacity to form an entire organism, while others can only differentiate into certain groups of tissues. In recent years, stem cells have also become popular in ophthalmology. Both stem cells found in ocular tissues and those derived from peripheral tissues are gaining attention for their use in ophthalmology. In ophthalmology, stem cells have a wide range of applications, from ocular surface and periocular tissue applications to retinal diseases. Some applications, such as limbal stem cell transplantation, have become common practices in clinical settings, while experimental and promising stem cell methods, such as anterior chamber stem cell transplants or subretinal supracoroidal stem cell transplants, are being investigated. Stem cells offer hope in ophthalmology for diseases that are unresponsive to traditional treatments, irreversible diseases, or dystrophic diseases that still lack approved treatments. The long-term effects of stem cell transplants in ophthalmology have not been clearly established, and the potential for tumor development due to uncontrolled proliferation has not been entirely eliminated. While there is a possibility of negative results from experimental studies and the emergence of concerning side effects, stem cells still hold promise as an alternative treatment option in ophthalmology.